Copyright Reports & Markets. All rights reserved.

Global DTP Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global DTP Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 DTaP
    • 1.3.3 Tdap
    • 1.3.4 DTwP
  • 1.4 Market Analysis by Combination
    • 1.4.1 Overview: Global DTP Vaccine Consumption Value by Combination: 2021 Versus 2025 Versus 2032
    • 1.4.2 Acellular Vaccines
    • 1.4.3 Whole-cell Vaccines
  • 1.5 Market Analysis by User
    • 1.5.1 Overview: Global DTP Vaccine Consumption Value by User: 2021 Versus 2025 Versus 2032
    • 1.5.2 Below 12 Months
    • 1.5.3 Above 12 Months
  • 1.6 Market Analysis by Application
    • 1.6.1 Overview: Global DTP Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Hospital
    • 1.6.3 Clinic
  • 1.7 Global DTP Vaccine Market Size & Forecast
    • 1.7.1 Global DTP Vaccine Consumption Value (2021 & 2025 & 2032)
    • 1.7.2 Global DTP Vaccine Sales Quantity (2021-2032)
    • 1.7.3 Global DTP Vaccine Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Sanofi Pasteur
    • 2.1.1 Sanofi Pasteur Details
    • 2.1.2 Sanofi Pasteur Major Business
    • 2.1.3 Sanofi Pasteur DTP Vaccine Product and Services
    • 2.1.4 Sanofi Pasteur DTP Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Sanofi Pasteur Recent Developments/Updates
  • 2.2 GSK
    • 2.2.1 GSK Details
    • 2.2.2 GSK Major Business
    • 2.2.3 GSK DTP Vaccine Product and Services
    • 2.2.4 GSK DTP Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 GSK Recent Developments/Updates
  • 2.3 Serum Institute of India
    • 2.3.1 Serum Institute of India Details
    • 2.3.2 Serum Institute of India Major Business
    • 2.3.3 Serum Institute of India DTP Vaccine Product and Services
    • 2.3.4 Serum Institute of India DTP Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Serum Institute of India Recent Developments/Updates
  • 2.4 KM Biologics
    • 2.4.1 KM Biologics Details
    • 2.4.2 KM Biologics Major Business
    • 2.4.3 KM Biologics DTP Vaccine Product and Services
    • 2.4.4 KM Biologics DTP Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 KM Biologics Recent Developments/Updates
  • 2.5 Wuhan Institute of Biological Products (WIBP)
    • 2.5.1 Wuhan Institute of Biological Products (WIBP) Details
    • 2.5.2 Wuhan Institute of Biological Products (WIBP) Major Business
    • 2.5.3 Wuhan Institute of Biological Products (WIBP) DTP Vaccine Product and Services
    • 2.5.4 Wuhan Institute of Biological Products (WIBP) DTP Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Wuhan Institute of Biological Products (WIBP) Recent Developments/Updates
  • 2.6 Walvax Biotechnology Co., Ltd.
    • 2.6.1 Walvax Biotechnology Co., Ltd. Details
    • 2.6.2 Walvax Biotechnology Co., Ltd. Major Business
    • 2.6.3 Walvax Biotechnology Co., Ltd. DTP Vaccine Product and Services
    • 2.6.4 Walvax Biotechnology Co., Ltd. DTP Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Walvax Biotechnology Co., Ltd. Recent Developments/Updates
  • 2.7 Chengdu Institute of Biological Products (CDIBP)
    • 2.7.1 Chengdu Institute of Biological Products (CDIBP) Details
    • 2.7.2 Chengdu Institute of Biological Products (CDIBP) Major Business
    • 2.7.3 Chengdu Institute of Biological Products (CDIBP) DTP Vaccine Product and Services
    • 2.7.4 Chengdu Institute of Biological Products (CDIBP) DTP Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Chengdu Institute of Biological Products (CDIBP) Recent Developments/Updates
  • 2.8 Beijing Minhai Biotechnology Co., Ltd.
    • 2.8.1 Beijing Minhai Biotechnology Co., Ltd. Details
    • 2.8.2 Beijing Minhai Biotechnology Co., Ltd. Major Business
    • 2.8.3 Beijing Minhai Biotechnology Co., Ltd. DTP Vaccine Product and Services
    • 2.8.4 Beijing Minhai Biotechnology Co., Ltd. DTP Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Beijing Minhai Biotechnology Co., Ltd. Recent Developments/Updates
  • 2.9 CanSino Biologics Inc.
    • 2.9.1 CanSino Biologics Inc. Details
    • 2.9.2 CanSino Biologics Inc. Major Business
    • 2.9.3 CanSino Biologics Inc. DTP Vaccine Product and Services
    • 2.9.4 CanSino Biologics Inc. DTP Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 CanSino Biologics Inc. Recent Developments/Updates

3 Competitive Environment: DTP Vaccine by Manufacturer

  • 3.1 Global DTP Vaccine Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global DTP Vaccine Revenue by Manufacturer (2021-2026)
  • 3.3 Global DTP Vaccine Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of DTP Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 DTP Vaccine Manufacturer Market Share in 2025
    • 3.4.3 Top 6 DTP Vaccine Manufacturer Market Share in 2025
  • 3.5 DTP Vaccine Market: Overall Company Footprint Analysis
    • 3.5.1 DTP Vaccine Market: Region Footprint
    • 3.5.2 DTP Vaccine Market: Company Product Type Footprint
    • 3.5.3 DTP Vaccine Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global DTP Vaccine Market Size by Region
    • 4.1.1 Global DTP Vaccine Sales Quantity by Region (2021-2032)
    • 4.1.2 Global DTP Vaccine Consumption Value by Region (2021-2032)
    • 4.1.3 Global DTP Vaccine Average Price by Region (2021-2032)
  • 4.2 North America DTP Vaccine Consumption Value (2021-2032)
  • 4.3 Europe DTP Vaccine Consumption Value (2021-2032)
  • 4.4 Asia-Pacific DTP Vaccine Consumption Value (2021-2032)
  • 4.5 South America DTP Vaccine Consumption Value (2021-2032)
  • 4.6 Middle East & Africa DTP Vaccine Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global DTP Vaccine Sales Quantity by Type (2021-2032)
  • 5.2 Global DTP Vaccine Consumption Value by Type (2021-2032)
  • 5.3 Global DTP Vaccine Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global DTP Vaccine Sales Quantity by Application (2021-2032)
  • 6.2 Global DTP Vaccine Consumption Value by Application (2021-2032)
  • 6.3 Global DTP Vaccine Average Price by Application (2021-2032)

7 North America

  • 7.1 North America DTP Vaccine Sales Quantity by Type (2021-2032)
  • 7.2 North America DTP Vaccine Sales Quantity by Application (2021-2032)
  • 7.3 North America DTP Vaccine Market Size by Country
    • 7.3.1 North America DTP Vaccine Sales Quantity by Country (2021-2032)
    • 7.3.2 North America DTP Vaccine Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe DTP Vaccine Sales Quantity by Type (2021-2032)
  • 8.2 Europe DTP Vaccine Sales Quantity by Application (2021-2032)
  • 8.3 Europe DTP Vaccine Market Size by Country
    • 8.3.1 Europe DTP Vaccine Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe DTP Vaccine Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific DTP Vaccine Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific DTP Vaccine Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific DTP Vaccine Market Size by Region
    • 9.3.1 Asia-Pacific DTP Vaccine Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific DTP Vaccine Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America DTP Vaccine Sales Quantity by Type (2021-2032)
  • 10.2 South America DTP Vaccine Sales Quantity by Application (2021-2032)
  • 10.3 South America DTP Vaccine Market Size by Country
    • 10.3.1 South America DTP Vaccine Sales Quantity by Country (2021-2032)
    • 10.3.2 South America DTP Vaccine Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa DTP Vaccine Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa DTP Vaccine Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa DTP Vaccine Market Size by Country
    • 11.3.1 Middle East & Africa DTP Vaccine Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa DTP Vaccine Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 DTP Vaccine Market Drivers
  • 12.2 DTP Vaccine Market Restraints
  • 12.3 DTP Vaccine Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of DTP Vaccine and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of DTP Vaccine
  • 13.3 DTP Vaccine Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 DTP Vaccine Typical Distributors
  • 14.3 DTP Vaccine Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global DTP Vaccine market size was valued at US$ 6136 million in 2025 and is forecast to a readjusted size of US$ 7744 million by 2032 with a CAGR of 3.4% during review period.
    In 2025, global DTP Vaccine production reached approximately 373 million doses, with an average global market price of around US$ 16 per dose. The DPT vaccine or DTP vaccine is a class of combination vaccine against three infectious diseases in humans: diphtheria, pertussis (whooping cough), and tetanus. In this report, we cover all the DTP-containing vaccines. Gross margin for the DTP Vaccine in general shows that manufacturers often achieve roughly 50–70% gross margins, depending on the producer, country, and contract.
    The global DTP Vaccine market continues to grow steadily, driven by rising awareness of whooping cough, expanding childhood immunization programs, and increasing recommendations for adolescent and adult Tdap boosters. Demand is especially strong in developing regions where pertussis remains endemic, while mature markets are supported by routine pregnancy immunization and periodic booster campaigns. Major manufacturers focus on improving vaccine safety, supply stability, and combination formulations such as DTaP, which simplify national immunization schedules. Although pricing and procurement are heavily influenced by government tenders and international organizations, overall market growth is supported by public-health initiatives, technological advances in acellular vaccine production, and efforts to increase global vaccination coverage. The DTP Vaccine industrial chain is a complex, highly regulated, and technology-intensive ecosystem that spans from upstream antigen research to downstream global immunization delivery. It is characterized by significant barriers to entry, stringent quality control, and a delicate balance between public health objectives and commercial viability. The chain begins with basic and applied research into Bordetella pertussis antigens. This includes the identification, genetic sequencing, and optimization of key immunogenic components such as Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA), Pertactin (PRN), and Fimbrial proteins (FIM). For acellular vaccines (aP), the upstream segment involves mastering large-scale fermentation, toxin purification, and detoxification (converting PT to Toxoid) processes. This stage also encompasses the production of specialized adjuvants (e.g., aluminum salts) and critical raw materials for cell culture media and buffers. Innovation here focuses on improving antigen yield, purity, stability, and developing novel adjuvant systems to enhance and prolong immunity. The demand for DTP Vaccines is driven by the persistent prevalence of whooping cough, growing awareness of immunization benefits, and expanding vaccination programs for infants, adolescents, and adults. Rising adoption of Tdap boosters during pregnancy and among healthcare workers further fuels market growth. Opportunities exist in developing countries where vaccination coverage is still limited, as well as in urban areas of developed nations with increasing focus on adult immunization and combination vaccines like DTaP to simplify schedules. Additionally, technological innovations in acellular vaccine production, improvements in cold-chain logistics, and government-supported public health initiatives create potential for new market entrants and partnerships. Manufacturers that can offer safe, effective, and easily deployable vaccines, along with reliable supply chains, are well-positioned to capture market share in both emerging and mature markets.
    Report Scope
    This report is a detailed and comprehensive analysis for global DTP Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global DTP Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Dose), 2021-2032
    Global DTP Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Dose), 2021-2032
    Global DTP Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Dose), 2021-2032
    Global DTP Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Dose), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for DTP Vaccine
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global DTP Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi Pasteur, GSK, Serum Institute of India, KM Biologics, Wuhan Institute of Biological Products (WIBP), Walvax Biotechnology Co., Ltd., Chengdu Institute of Biological Products (CDIBP), Beijing Minhai Biotechnology Co., Ltd., CanSino Biologics Inc., etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    DTP Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market Segmentation
    Market segment by Type
    DTaP
    Tdap
    DTwP
    Market segment by Combination
    Acellular Vaccines
    Whole-cell Vaccines
    Market segment by User
    Below 12 Months
    Above 12 Months
    Market segment by Application
    Hospital
    Clinic
    Major players covered
    Sanofi Pasteur
    GSK
    Serum Institute of India
    KM Biologics
    Wuhan Institute of Biological Products (WIBP)
    Walvax Biotechnology Co., Ltd.
    Chengdu Institute of Biological Products (CDIBP)
    Beijing Minhai Biotechnology Co., Ltd.
    CanSino Biologics Inc.
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    Chapter Outline
    Chapter 1, to describe DTP Vaccine product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of DTP Vaccine, with price, sales quantity, revenue, and global market share of DTP Vaccine from 2021 to 2026.
    Chapter 3, the DTP Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the DTP Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and DTP Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of DTP Vaccine.
    Chapter 14 and 15, to describe DTP Vaccine sales channel, distributors, customers, research findings and conclusion.

    Buy now